PMC:7253235 / 39796-43444
Annnotations
LitCovid_Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T7 | 2145-2148 | https://glytoucan.org/Structures/Glycans/G00063MO | denotes | CAD |
T8 | 3550-3553 | https://glytoucan.org/Structures/Glycans/G00063MO | denotes | CAD |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1371 | 2416-2420 | Gene | denotes | HER2 | Gene:2064 |
1372 | 2422-2426 | Gene | denotes | BRAF | Gene:673 |
1373 | 2427-2430 | Gene | denotes | MEK | Gene:5609 |
1374 | 423-430 | Species | denotes | patient | Tax:9606 |
1375 | 536-543 | Species | denotes | patient | Tax:9606 |
1376 | 818-828 | Species | denotes | outpatient | Tax:9606 |
1377 | 1371-1379 | Species | denotes | patients | Tax:9606 |
1378 | 1946-1954 | Species | denotes | patients | Tax:9606 |
1379 | 2343-2351 | Species | denotes | patients | Tax:9606 |
1380 | 2535-2543 | Species | denotes | Patients | Tax:9606 |
1381 | 2740-2748 | Species | denotes | patients | Tax:9606 |
1382 | 3102-3109 | Species | denotes | patient | Tax:9606 |
1383 | 3136-3144 | Species | denotes | patients | Tax:9606 |
1384 | 192-200 | Disease | denotes | COVID-19 | MESH:C000657245 |
1385 | 229-235 | Disease | denotes | cancer | MESH:D009369 |
1386 | 396-402 | Disease | denotes | cancer | MESH:D009369 |
1387 | 451-459 | Disease | denotes | COVID-19 | MESH:C000657245 |
1388 | 462-468 | Disease | denotes | Cancer | MESH:D009369 |
1389 | 684-692 | Disease | denotes | COVID-19 | MESH:C000657245 |
1390 | 797-803 | Disease | denotes | cancer | MESH:D009369 |
1391 | 941-947 | Disease | denotes | cancer | MESH:D009369 |
1392 | 1072-1080 | Disease | denotes | COVID-19 | MESH:C000657245 |
1393 | 1281-1286 | Disease | denotes | tumor | MESH:D009369 |
1394 | 1501-1515 | Disease | denotes | Cardiotoxicity | MESH:D066126 |
1395 | 1535-1541 | Disease | denotes | cancer | MESH:D009369 |
1396 | 1560-1574 | Disease | denotes | cardiomyopathy | MESH:D009202 |
1397 | 1576-1587 | Disease | denotes | arrhythmias | MESH:D001145 |
1398 | 1593-1601 | Disease | denotes | ischemic | MESH:D007511 |
1399 | 1629-1635 | Disease | denotes | cancer | MESH:D009369 |
1400 | 1689-1697 | Disease | denotes | COVID-19 | MESH:C000657245 |
1401 | 1711-1729 | Disease | denotes | cardiac and cancer | MESH:D006338 |
1402 | 1754-1763 | Disease | denotes | mortality | MESH:D003643 |
1403 | 2005-2008 | Disease | denotes | CVD | MESH:D002318 |
1404 | 2063-2075 | Disease | denotes | dyslipidemia | MESH:D050171 |
1405 | 2150-2161 | Disease | denotes | arrhythmias | MESH:D001145 |
1406 | 2166-2169 | Disease | denotes | CHF | |
1407 | 2293-2319 | Disease | denotes | arrhythmias Cardiotoxicity | MESH:D066126 |
1408 | 2336-2342 | Disease | denotes | cancer | MESH:D009369 |
1409 | 2386-2392 | Disease | denotes | cancer | MESH:D009369 |
1410 | 2555-2569 | Disease | denotes | cardiotoxicity | MESH:D066126 |
1411 | 2621-2635 | Disease | denotes | cardiotoxicity | MESH:D066126 |
1412 | 2857-2871 | Disease | denotes | cardiotoxicity | MESH:D066126 |
1413 | 3050-3062 | Disease | denotes | dyslipidemia | MESH:D050171 |
1414 | 3253-3256 | Disease | denotes | CHF | |
1415 | 3289-3295 | Disease | denotes | cancer | MESH:D009369 |
1418 | 63-70 | Species | denotes | patient | Tax:9606 |
1419 | 82-90 | Disease | denotes | COVID-19 | MESH:C000657245 |
1423 | 3522-3548 | Disease | denotes | CVD cardiovascular disease | MESH:D002318 |
1424 | 3550-3577 | Disease | denotes | CAD coronary artery disease | MESH:D003324 |
1425 | 3579-3607 | Disease | denotes | CHF congestive heart failure | MESH:D006333 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T116 | 370-384 | Body_part | denotes | immune systems | http://purl.org/sig/ont/fma/fma9825 |
T117 | 1236-1249 | Body_part | denotes | immune system | http://purl.org/sig/ont/fma/fma9825 |
T118 | 3164-3168 | Body_part | denotes | face | http://purl.org/sig/ont/fma/fma24728 |
T119 | 3172-3176 | Body_part | denotes | face | http://purl.org/sig/ont/fma/fma24728 |
T120 | 3214-3219 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
T121 | 3229-3234 | Body_part | denotes | lipid | http://purl.org/sig/ont/fma/fma67264 |
T122 | 3393-3404 | Body_part | denotes | bone marrow | http://purl.org/sig/ont/fma/fma9608 |
T123 | 3554-3569 | Body_part | denotes | coronary artery | http://purl.org/sig/ont/fma/fma49893 |
T124 | 3594-3599 | Body_part | denotes | heart | http://purl.org/sig/ont/fma/fma7088 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T53 | 370-384 | Body_part | denotes | immune systems | http://purl.obolibrary.org/obo/UBERON_0002405 |
T54 | 1236-1249 | Body_part | denotes | immune system | http://purl.obolibrary.org/obo/UBERON_0002405 |
T55 | 3164-3168 | Body_part | denotes | face | http://purl.obolibrary.org/obo/UBERON_0001456 |
T56 | 3172-3176 | Body_part | denotes | face | http://purl.obolibrary.org/obo/UBERON_0001456 |
T57 | 3214-3219 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
T58 | 3393-3404 | Body_part | denotes | bone marrow | http://purl.obolibrary.org/obo/UBERON_0002371 |
T59 | 3554-3569 | Body_part | denotes | coronary artery | http://purl.obolibrary.org/obo/UBERON_0001621 |
T60 | 3563-3569 | Body_part | denotes | artery | http://purl.obolibrary.org/obo/UBERON_0001637 |
T61 | 3594-3599 | Body_part | denotes | heart | http://purl.obolibrary.org/obo/UBERON_0000948 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T398 | 82-90 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T399 | 192-200 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T400 | 229-235 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T401 | 396-402 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T402 | 451-459 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T403 | 462-468 | Disease | denotes | Cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T404 | 684-692 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T405 | 797-803 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T406 | 941-947 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T407 | 1072-1080 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T408 | 1281-1286 | Disease | denotes | tumor | http://purl.obolibrary.org/obo/MONDO_0005070 |
T409 | 1535-1541 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T410 | 1560-1574 | Disease | denotes | cardiomyopathy | http://purl.obolibrary.org/obo/MONDO_0004994 |
T411 | 1576-1587 | Disease | denotes | arrhythmias | http://purl.obolibrary.org/obo/MONDO_0007263 |
T412 | 1629-1635 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T413 | 1689-1697 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T414 | 1723-1729 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T415 | 2052-2055 | Disease | denotes | HTN | http://purl.obolibrary.org/obo/MONDO_0005044 |
T416 | 2063-2075 | Disease | denotes | dyslipidemia | http://purl.obolibrary.org/obo/MONDO_0002525 |
T417 | 2145-2148 | Disease | denotes | CAD | http://purl.obolibrary.org/obo/MONDO_0005010|http://purl.obolibrary.org/obo/MONDO_0018922 |
T419 | 2150-2161 | Disease | denotes | arrhythmias | http://purl.obolibrary.org/obo/MONDO_0007263 |
T420 | 2166-2169 | Disease | denotes | CHF | http://purl.obolibrary.org/obo/MONDO_0005009 |
T421 | 2293-2304 | Disease | denotes | arrhythmias | http://purl.obolibrary.org/obo/MONDO_0007263 |
T422 | 2336-2342 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T423 | 2386-2392 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T424 | 3050-3062 | Disease | denotes | dyslipidemia | http://purl.obolibrary.org/obo/MONDO_0002525 |
T425 | 3253-3256 | Disease | denotes | CHF | http://purl.obolibrary.org/obo/MONDO_0005009 |
T426 | 3289-3295 | Disease | denotes | cancer | http://purl.obolibrary.org/obo/MONDO_0004992 |
T427 | 3526-3548 | Disease | denotes | cardiovascular disease | http://purl.obolibrary.org/obo/MONDO_0004995 |
T428 | 3550-3553 | Disease | denotes | CAD | http://purl.obolibrary.org/obo/MONDO_0005010|http://purl.obolibrary.org/obo/MONDO_0018922 |
T430 | 3554-3577 | Disease | denotes | coronary artery disease | http://purl.obolibrary.org/obo/MONDO_0005010 |
T431 | 3563-3577 | Disease | denotes | artery disease | http://purl.obolibrary.org/obo/MONDO_0000473 |
T432 | 3579-3582 | Disease | denotes | CHF | http://purl.obolibrary.org/obo/MONDO_0005009 |
T433 | 3583-3607 | Disease | denotes | congestive heart failure | http://purl.obolibrary.org/obo/MONDO_0005009 |
T434 | 3594-3607 | Disease | denotes | heart failure | http://purl.obolibrary.org/obo/MONDO_0005252 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T304 | 308-311 | http://purl.obolibrary.org/obo/CLO_0002199 | denotes | CAR |
T305 | 370-384 | http://purl.obolibrary.org/obo/UBERON_0002405 | denotes | immune systems |
T306 | 693-700 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T307 | 1060-1067 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T308 | 1236-1249 | http://purl.obolibrary.org/obo/UBERON_0002405 | denotes | immune system |
T309 | 1786-1793 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T310 | 2910-2917 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T311 | 3164-3168 | http://purl.obolibrary.org/obo/UBERON_0001456 | denotes | face |
T312 | 3172-3176 | http://purl.obolibrary.org/obo/UBERON_0001456 | denotes | face |
T313 | 3214-3219 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
T314 | 3214-3219 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
T315 | 3393-3397 | http://purl.obolibrary.org/obo/UBERON_0002481 | denotes | bone |
T316 | 3422-3425 | http://purl.obolibrary.org/obo/CLO_0002199 | denotes | CAR |
T317 | 3563-3569 | http://purl.obolibrary.org/obo/UBERON_0001637 | denotes | artery |
T318 | 3563-3569 | http://www.ebi.ac.uk/efo/EFO_0000814 | denotes | artery |
T319 | 3594-3599 | http://purl.obolibrary.org/obo/UBERON_0000948 | denotes | heart |
T320 | 3594-3599 | http://purl.obolibrary.org/obo/UBERON_0007100 | denotes | heart |
T321 | 3594-3599 | http://purl.obolibrary.org/obo/UBERON_0015228 | denotes | heart |
T322 | 3594-3599 | http://www.ebi.ac.uk/efo/EFO_0000815 | denotes | heart |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T115 | 560-568 | Chemical | denotes | carriers | http://purl.obolibrary.org/obo/CHEBI_78059 |
T116 | 1837-1845 | Chemical | denotes | carriers | http://purl.obolibrary.org/obo/CHEBI_78059 |
T117 | 2427-2430 | Chemical | denotes | MEK | http://purl.obolibrary.org/obo/CHEBI_28398 |
T118 | 2643-2657 | Chemical | denotes | anthracyclines | http://purl.obolibrary.org/obo/CHEBI_48120|http://purl.obolibrary.org/obo/CHEBI_49322 |
T120 | 3229-3234 | Chemical | denotes | lipid | http://purl.obolibrary.org/obo/CHEBI_18059 |
T121 | 3437-3444 | Chemical | denotes | antigen | http://purl.obolibrary.org/obo/CHEBI_59132 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T28 | 2241-2247 | http://purl.obolibrary.org/obo/GO_0048511 | denotes | rhythm |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T215 | 54-62 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T216 | 107-115 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T217 | 229-235 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
T218 | 396-402 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
T219 | 462-468 | Phenotype | denotes | Cancer | http://purl.obolibrary.org/obo/HP_0002664 |
T220 | 797-803 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
T221 | 941-947 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
T222 | 1125-1133 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T223 | 1134-1142 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T224 | 1281-1286 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
T225 | 1535-1541 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
T226 | 1560-1574 | Phenotype | denotes | cardiomyopathy | http://purl.obolibrary.org/obo/HP_0001638 |
T227 | 1576-1587 | Phenotype | denotes | arrhythmias | http://purl.obolibrary.org/obo/HP_0011675 |
T228 | 1629-1635 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
T229 | 1658-1666 | Phenotype | denotes | oncology | http://purl.obolibrary.org/obo/HP_0002664 |
T230 | 1723-1729 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
T231 | 2063-2075 | Phenotype | denotes | dyslipidemia | http://purl.obolibrary.org/obo/HP_0003119 |
T232 | 2150-2161 | Phenotype | denotes | arrhythmias | http://purl.obolibrary.org/obo/HP_0011675 |
T233 | 2166-2169 | Phenotype | denotes | CHF | http://purl.obolibrary.org/obo/HP_0001635 |
T234 | 2293-2304 | Phenotype | denotes | arrhythmias | http://purl.obolibrary.org/obo/HP_0011675 |
T235 | 2336-2342 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
T236 | 2386-2392 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
T237 | 3050-3062 | Phenotype | denotes | dyslipidemia | http://purl.obolibrary.org/obo/HP_0003119 |
T238 | 3253-3256 | Phenotype | denotes | CHF | http://purl.obolibrary.org/obo/HP_0001635 |
T239 | 3289-3295 | Phenotype | denotes | cancer | http://purl.obolibrary.org/obo/HP_0002664 |
T240 | 3526-3548 | Phenotype | denotes | cardiovascular disease | http://purl.obolibrary.org/obo/HP_0001626 |
T241 | 3579-3582 | Phenotype | denotes | CHF | http://purl.obolibrary.org/obo/HP_0001635 |
T242 | 3583-3607 | Phenotype | denotes | congestive heart failure | http://purl.obolibrary.org/obo/HP_0001635 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T250 | 0-99 | Sentence | denotes | Table 2 Proposed special considerations of the cardio-oncology patient during the COVID-19 pandemic |
T251 | 100-209 | Sentence | denotes | Cardio-oncology aspect of care Theoretical areas of concern Proposed Strategies to Mitigate COVID-19 Exposure |
T252 | 210-459 | Sentence | denotes | Initiating/ongoing cancer treatments (i.e., chemotherapy, targeted therapies, immunotherapy, BMT, CAR-T), and timing of oncologic-related surgery • Compromised immune systems induced by cancer treatments may make patient more susceptible to COVID-19 |
T253 | 460-580 | Sentence | denotes | • Cancer treatments may require healthcare facility/inpatient stay exposing patient to asymptomatic carriers (i.e., HCW) |
T254 | 581-672 | Sentence | denotes | • Delaying of potential critical, life-prolonging surgery as it may be deemed as “elective” |
T255 | 673-883 | Sentence | denotes | • Ensuring COVID-19 testing adequacy by healthcare providers • Implementation of universal PPE and social distancing during cancer treatments in outpatient/inpatient settings, and with family members/caretakers |
T256 | 884-1019 | Sentence | denotes | • Weighing risk-benefit of postponing/delaying timing of cancer treatments/surgery to minimize exposure to inpatient healthcare setting |
T257 | 1020-1080 | Sentence | denotes | • Preoperative/procedural screening and testing for COVID-19 |
T258 | 1081-1179 | Sentence | denotes | • Telemedicine for routine follow-up cardio-oncology/oncology visits unless clinically symptomatic |
T259 | 1180-1294 | Sentence | denotes | • Research efforts investigating earlier utilization of immune system restorative measures post anti-tumor therapy |
T260 | 1295-1413 | Sentence | denotes | • Consideration of delaying myeloablative therapies and immunotherapies for patients in clinical remission if possible |
T261 | 1414-1500 | Sentence | denotes | • Consideration of minimizing surveillance/staging imaging during and after treatments |
T262 | 1501-1763 | Sentence | denotes | Cardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality |
T263 | 1764-1926 | Sentence | denotes | • Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms |
T264 | 1927-2076 | Sentence | denotes | • Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia) |
T265 | 2077-2222 | Sentence | denotes | • Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary |
T266 | 2223-2304 | Sentence | denotes | • Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias |
T267 | 2305-2532 | Sentence | denotes | Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months) |
T268 | 2533-2768 | Sentence | denotes | • Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic |
T269 | 2769-2930 | Sentence | denotes | • Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable |
T270 | 2931-3004 | Sentence | denotes | • Limited imaging protocols to evaluate LVEF to minimize acquisition time |
T271 | 3005-3109 | Sentence | denotes | • Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient |
T272 | 3110-3257 | Sentence | denotes | • Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF) |
T273 | 3258-3388 | Sentence | denotes | • Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms |
T274 | 3389-3648 | Sentence | denotes | BMT bone marrow transplantation, CAR-T chimeric antigen receptor therapy, HCW healthcare workers, PPE personal protective equipment, CVD cardiovascular disease, CAD coronary artery disease, CHF congestive heart failure, LVEF left ventricular ejection fraction |